These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 31858669)

  • 1. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Vuorio A; Watts GF; Kovanen PT
    Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
    Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
    Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž
    Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a): the revenant.
    Gencer B; Kronenberg F; Stroes ES; Mach F
    Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
    Nicholls SJ; Nelson AJ; Ditmarsch M; Kastelein JJP; Ballantyne CM; Ray KK; Navar AM; Nissen SE; Golberg AC; Brunham LR; Curcio D; Wuerdeman E; Neild A; Kling D; Hsieh A; Dicklin MR; Ference BA; Laufs U; Banach M; Mehran R; Catapano AL; Davidson MH
    Am Heart J; 2024 Aug; 274():32-45. PubMed ID: 38705341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Existing and emerging therapies for the treatment of familial hypercholesterolemia.
    Rosenson RS
    J Lipid Res; 2021; 62():100060. PubMed ID: 33716107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
    J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.